ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia

This study has been completed.

Sponsors and Collaborators: NCI - Center for Cancer Research-Medical Oncology
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00019032
  Purpose

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have chronic lymphocytic leukemia.


Condition Intervention Phase
Leukemia
Drug: monoclonal antibody Mik-beta-1
Phase I

MedlinePlus related topics:   Cancer    Leukemia, Adult Acute    Leukemia, Adult Chronic   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment
Official Title:   PHASE I STUDY OF T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA USING THE MIK-BETA 1 MONOCLONAL ANTIBODY DIRECTED TOWARD THE IL-2R BETA SUBUNIT

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment:   25
Study Start Date:   March 1996

Detailed Description:

OBJECTIVES:

  • Evaluate the toxicity of murine monoclonal antibody Mik-beta-1 (MOAB Mik-beta-1) in patients with T-cell large granular lymphocytic leukemia associated with granulocytopenia, anemia, or thrombocytopenia.
  • Determine the clinical response in patients treated with this drug.
  • Assess the effect of this drug on the number of circulating CD3+, CD8+ expressing granular lymphocytes and the number of polymorphonuclear leukocytes, red blood cells, and platelets in this patient population.
  • Monitor patients for the time course of decline in circulating infused MOAB Mik-beta-1 and for the production of human antibodies to IV infused murine MOAB Mik-beta-1.

OUTLINE: This is a dose-escalation study.

Patients receive monoclonal antibody Mik-beta-1 (MOAB Mik-beta-1) IV over 2 hours on days 1, 4, 7, and 10. Patients achieving a complete response (CR) or partial response (PR) may receive 1 additional course beginning no sooner than 4 weeks after completion of the first course, in the absence of antibodies to MOAB Mik-beta-1. Treatment continues in the absence of disease progression, unacceptable toxicity, or severe allergic reaction.

Cohorts of 3-6 patients receive escalating doses of MOAB Mik-beta-1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at 6-10 days and at 4-6 weeks after therapy. Patients with a PR or CR may be followed every 6 months for 2 years or until relapse. All patients are followed for survival.

PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed T-cell large granular lymphocytic (T-LGL) leukemia associated with clinically significant hematocytopenia demonstrated by one of the following values while off growth factor support:

    • Absolute neutrophil count less than 1,000/mm^3
    • Hemoglobin less than 8 g/dL
    • Platelet count less than 50,000/mm^3
  • Clinically evaluable disease with peripheral blood T-LGL leukemia cells expressing the CD3+, CD8+ phenotype detectable by FACS
  • Monoclonal T-cell population in peripheral blood (circulating mononuclear cells) demonstrated by TCR beta or gamma chain gene rearrangement

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 50-100%

Life expectancy:

  • More than 2 months

Hematopoietic:

  • See Disease Characteristics
  • No active major bleeding episode within the past 4 weeks

Hepatic:

  • Direct bilirubin less than 1.5 mg/dL

Renal:

  • Creatinine less than 2.0 mg/dL

Other:

  • No concurrent serious active infection
  • Patients with fever without apparent site of infection may begin study while on antibiotics as long as the following are true:

    • No pathogenic organism in culture
    • Afebrile (maximum temperature less than 38°C) for at least 5 days
  • HIV negative
  • No other primary cancer other than basal cell skin cancer
  • Not pregnant or nursing
  • Negative pregnancy test

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 4 weeks since prior interferon
  • Concurrent filgrastim (G-CSF), sargramostim (GM-CSF), interleukin-11, or similar sustained-release/long-acting product (e.g., pegylated G-CSF) allowed if dose established at least 4 weeks prior to study participation
  • No concurrent interferon

Chemotherapy:

  • At least 4 weeks since prior chemotherapy
  • No concurrent chemotherapy

Endocrine therapy:

  • Concurrent corticosteroids allowed if dose established at least 3 weeks prior to study participation

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Other:

  • At least 1 week since completion of prior antibiotic regimen for serious infectious episode
  • No other concurrent investigational drugs
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00019032

Locations
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support    
      Bethesda, Maryland, United States, 20892-1182

Sponsors and Collaborators
NCI - Center for Cancer Research-Medical Oncology
National Cancer Institute (NCI)

Investigators
Study Chair:     Thomas A. Waldmann, MD     NCI - Metabolism Branch;MET    
  More Information


Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   CDR0000064038, NCI-95-C-0054K
First Received:   July 11, 2001
Last Updated:   October 18, 2008
ClinicalTrials.gov Identifier:   NCT00019032
Health Authority:   United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
refractory chronic lymphocytic leukemia  
T-cell large granular lymphocyte leukemia  

Study placed in the following topic categories:
Chronic lymphocytic leukemia
Leukemia, Lymphoid
Large granular lymphocyte leukemia
Immunoproliferative Disorders
Antibodies, Monoclonal
Leukemia
Lymphatic Diseases
Antibodies
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, T-Cell
Leukemia, B-Cell
Lymphoproliferative Disorders
Leukemia, Large Granular Lymphocytic

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Immunologic Factors
Immune System Diseases
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers